logo
ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Globe and Mail5 days ago
Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. ('Regional') (OTCBQ: RHEP) (OTCQB: RHEPA) (OTCQB: RHEPB), a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care, announced today that leading independent proxy advisory firm Institutional Shareholder Services Inc. ('ISS') recommended that Regional shareholders vote ' FOR ': (1) the approval of the Amended and Restated Agreement and Plan of Merger, dated April 14, 2025 (as amended, the 'Merger Agreement'), by and between Regional and SunLink Health Systems, Inc. (the 'Merger Proposal'), (2) the approval of the issuance of shares of Regional common stock and Regional Series D 8% Cumulative Convertible Redeemable Participating Preferred Shares (the 'Regional Series D preferred stock') in connection with the merger (the 'Share Issuance Proposal'), and (3) the approval to adjourn the Regional special meeting to solicit additional proxies in favor of the Merger Proposal or the Share Issuance Proposal if there are insufficient votes at the time of such adjournment to approve the Merger Proposal or the Share Issuance Proposal.
In its July 23, 2025 report, ISS noted: 1
The strategic rationale for the merger appears sound considering the pre-tax cost synergies and enhanced possibility of long-term profitability.
The outperformance of SunLink and Regional since announcement suggests that investors view the proposed combination favorably.
Brent Morrison, CFA, Chairman and Chief Executive Officer of Regional, stated, 'Regional is pleased that ISS concluded that support for this transaction was warranted. Regional is even more pleased that, of the proxies received to date, approximately 80% of Regional's common stock shareholders see it the same way.'
SPECIAL MEETING OF SHAREHOLDERS
July 29, 2025 at 10 am ET
YOUR VOTE IS IMPORTANT. VOTE TODAY!
About Regional Health Properties
Regional Health Properties, Inc., a Georgia corporation, is a self-managed healthcare real estate investment company that invests primarily in real estate purposed for senior living and long-term care. For more information, visit www.regionalhealthproperties.com.
NO OFFER OR SOLICITATION
Communications in this press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any proxy vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended (the 'Securities Act').
ADDITIONAL INFORMATION
The proposed merger will be submitted to both the Regional and SunLink shareholders for their consideration. In connection with the proposed merger, Regional filed a Registration Statement on Form S-4 (File No. 333-286975) (the 'Registration Statement') with SEC that includes a joint proxy statement/prospectus for Regional and SunLink, which was sent to common stock shareholders of Regional and common stock shareholders of SunLink on or about June 30, 2025.
INVESTORS ARE URGED TO READ THE REGISTRATION STATEMENT AND THE CORRESPONDING JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED MERGER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION.
IN ADDITION, INVESTORS ARE URGED TO READ THE TENDER OFFER STATEMENT ON SCHEDULE TO FILED WITH THE SEC ON JULY 18, 2025 REGARDING A PROPOSED TENDER OFFER, AS WELL AS ANY OTHER RELEVANT DOCUMENTS FILED WITH THE SEC, TOGETHER WITH ALL AMENDMENTS AND SUPPLEMENTS TO THOSE DOCUMENTS, AS THEY WILL CONTAIN IMPORTANT INFORMATION.
You are able to obtain a copy of the joint proxy statement/prospectus, as well as other filings containing information about Regional and SunLink, without charge, at the SEC's website (http://www.sec.gov) or by accessing Regional's website (http://www.regionalhealthproperties.com) under the tab 'Investor Relations' or by accessing SunLink's website (http://www.sunlinkhealth.com) under the tab 'Investors.' Copies of the joint proxy statement/prospectus can also be obtained, without charge, by directing a request to Investor Relations, Regional Health Properties, Inc., 1050 Crown Pointe Parkway, Suite 720, Atlanta, Georgia, 30338, telephone 678-869-5116 or to Investor Relations, SunLink Health Systems, Inc., 900 Circle 75 Parkway, Suite 690, Atlanta, Georgia, 30339, telephone 770-933-7004.
Regional and SunLink and certain of their directors and executive officers may be deemed to be participants in the solicitation of proxies from the shareholders of Regional and SunLink in connection with the proposed merger. Information about the directors and executive officers of Regional is set forth in the proxy statement for Regional's Annual Report on Form 10-K for the year ended December 31, 2024 (the 'Regional Annual Report'), as filed with the SEC on March 31, 2025, which information may be updated by Regional from time to time in subsequent filings with the SEC. Information about the directors and executive officers of SunLink is set forth in the proxy statement for SunLink's Amendment No. 1 to Annual Report on Form 10-K/, as filed with the SEC on October 25, 2024, which information may be updated by SunLink from time to time in subsequent filings with the SEC. Additional information about the interests of those participants and other persons who may be deemed participants in the transaction may also be obtained by reading the joint proxy statement/prospectus relating to the proposed merger when it becomes available. Free copies of this document may be obtained as described above.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended. Such forward-looking statements can often, but not always, be identified by the use of words like 'believe', 'continue', 'pattern', 'estimate', 'project', 'intend', 'anticipate', 'expect' and similar expressions or future or conditional verbs such as 'will', 'would', 'should', 'could', 'might', 'can', 'may', or similar expressions. These forward-looking statements include, but are not limited to, statements relating to the expected benefits of the proposed merger between Regional and SunLink, including pre-tax cost synergies and profitability, other statements of expectations regarding the merger, and other statements of Regional's goals, intentions and expectations.
These forward-looking statements are subject to significant risks, assumptions and uncertainties that may cause results to differ materially from those set forth in forward-looking statements, including, among other things:
the risk that the businesses of Regional and SunLink will not be integrated successfully or such integration may be more difficult, time-consuming or costly than expected;
expected revenue synergies and cost savings from the merger may not be fully realized or realized within the expected time frame;
revenues following the merger may be lower than expected;
customer, vendor and employee relationships and business operations may be disrupted by the merger;
the ability to obtain required regulatory approvals or the approvals of Regional's or SunLink's shareholders, and the ability to complete the merger on the expected timeframe;
the costs and effects of litigation and the possible unexpected or adverse outcomes of such litigation;
the ability of Regional and SunLink to meet the initial or continued listing requirements or rules of the NYSE American LLC or the OTCQB, as applicable, and to maintain the listing or trading, as applicable, of securities thereon;
possible changes in economic and business conditions;
the impacts of epidemics, pandemics or other infectious disease outbreaks;
the existence or exacerbation of general geopolitical instability and uncertainty;
possible changes in monetary and fiscal policies, and laws and regulations;
competitive factors in the healthcare industry;
Regional's dependence on the operating success of its operators;
the amount of, and Regional's ability to service, its indebtedness;
covenants in Regional's debt agreements that may restrict its ability to make investments, incur additional indebtedness and refinance indebtedness on favorable terms;
the effect of increasing healthcare regulation and enforcement on Regional's operators and the dependence of Regional's operators on reimbursement from governmental and other third-party payors;
the relatively illiquid nature of real estate investments;
the impact of litigation and rising insurance costs on the business of Regional's operators;
the effect of Regional's operators declaring bankruptcy, becoming insolvent or failing to pay rent as due;
the ability of any of Regional's operators in bankruptcy to reject unexpired lease obligations and to impede its ability to collect unpaid rent or interest during the pendency of a bankruptcy proceeding and retain security deposits for the debtor's obligations;
Regional's ability to find replacement operators and the impact of unforeseen costs in acquiring new properties; and
other risks and factors identified in (i) Regional's cautionary language included under the headings 'Statement Regarding Forward-Looking Statements' and 'Risk Factors' in the Regional Annual Report, and other documents subsequently filed by Regional with the SEC and (ii) SunLink's cautionary language included under the headings 'Forward-Looking Statements' and 'Risk Factors' in SunLink's Annual Report on Form 10-K for the year ended June 30, 2024, and other documents subsequently filed by SunLink with the SEC.
Neither Regional nor SunLink undertake any obligation to update any forward-looking statement, whether written or oral, relating to the matters discussed in this press release. In addition, Regional's and SunLink's past results of operations do not necessarily indicate either of their anticipated future results, whether the merger is effectuated or not.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Tesla signs US$4.3 billion LGES battery deal, source says, reducing China reliance
Tesla signs US$4.3 billion LGES battery deal, source says, reducing China reliance

CTV News

time22 minutes ago

  • CTV News

Tesla signs US$4.3 billion LGES battery deal, source says, reducing China reliance

An electric plug decal is seen on the back of a Tesla electric car in Trenton, N.J. (AP / Mel Evans) SEOUL — South Korea's LG Energy Solution (LGES) has signed a US$4.3 billion deal to supply Tesla with energy storage system batteries, said a person familiar with the matter, as the U.S. company looks to reduce reliance on Chinese imports due to tariffs. The lithium iron phosphate (LFP) batteries will be supplied from LGES's U.S. factory in Michigan, the person said on condition of anonymity because the details were not public. LGES announced earlier on Wednesday that it had signed a US$4.3 billion contract to supply LFP batteries over three years globally, without identifying the customer or saying if they would be used in vehicles or energy storage systems. The South Korean company said last week it would try to offset sluggish electric vehicle demand by increasing sales of storage batteries thanks to a global surge in demand for power driven by data centers to train artificial intelligence. 'In accordance with our agreement, we are unable to disclose the customer's identity due to confidentiality obligations,' LGES told Reuters. Tesla did not immediately respond to a request for comment. Tesla Chief Financial Officer Vaibhav Taneja said in April that U.S. tariffs had an 'outsized' impact on its energy business, since it sources LFP batteries from China. 'We will also be working on securing additional supply chain from non-China-based suppliers, but it will take time,' he said. Tesla this week also announced a US$16.5 billion deal to buy chips from Samsung Electronics' factory in Texas as South Korean companies expand their U.S. presence to meet local demand. Three South Korean cabinet-level officials met U.S. Commerce Secretary Howard Lutnick in Washington in a push to close a trade deal ahead of an August 1 deadline for 25 per cent tariffs on U.S. imports from South Korea to kick in, Seoul said on Wednesday. U.S. production LGES is one of the few U.S. producers of LFP batteries, a battery chemistry long dominated by Chinese rivals that have little presence in the U.S. market. It started production of LFP batteries at its Michigan factory in May. The company said it was considering converting some electric vehicle battery production lines in the United States to cater to energy storage systems in response to slowing EV demand. LGES said the contract would last from August 2027 to July 2030 and included an option to extend the deal period by up to seven years and to increase supply volumes depending on discussions with its customer. 'Other players, including South Korean firms like Samsung SDI and SK On, have yet to enter the U.S. LFP market, allowing LGES to enjoy a first-mover advantage,' said Cho Hyun-ryul, a senior analyst at Samsung Securities. 'While rivals have announced plans, LGES remains the only one actively producing at scale.' Tesla's energy storage and generation business accounts for just over ten per cent of its revenue but it has been a bright spot for the company as it struggles with slowing car sales and upcoming cuts to U.S. government support for EVs. 'Energy is growing really well despite headwinds from tariffs and various supply chain challenges,' Tesla CEO Elon Musk said on an earnings call last week. 'I think not that many people appreciate just how gigantic the scale of battery demand is.' Tesla has said its first LFP cell manufacturing facility will be online by the end of the year, but the in-house factory in Nevada will likely account for a small portion of its demand. --- Reporting by Heekyong Yang and Hyunjoo Jin; Editing by Jamie Freed

‘Ozempic face' may be driving a cosmetic surgery boom
‘Ozempic face' may be driving a cosmetic surgery boom

CTV News

time22 minutes ago

  • CTV News

‘Ozempic face' may be driving a cosmetic surgery boom

About two years ago, celebrity cosmetic dermatologist Dr. Paul Jarrod Frank noticed a new type of patient arriving at his New York practice. Amid an explosion in the number of Americans losing weight with drugs like Ozempic, he saw a 'dramatic spike' in clients experiencing unwelcome side effects. 'Although they felt much better losing weight, in some ways they felt they looked older,' he said via a voice note. 'And this was due to the loss of volume in their face.' Frank started using the term 'Ozempic face' — a label he believes he coined — to describe the phenomenon. It has since become a social media byword for the sagging skin and hollowed-out appearance that can accompany the use of GLP-1 medications like semaglutide (the active ingredient in branded drugs such as Ozempic and Wegovy). 'Usually, with people from their mid-40s and above, once you start losing 10-plus pounds, you can get this kind of deflated look,' said Frank, who is the founder of aesthetic health care brand PFRANKMD and the author of 'The Pro-Aging Playbook.' 'Certainly, people losing 20 or 30-plus pounds are going to have this problem.' Semaglutide works by stimulating the pancreas to trigger insulin production, curbing users' appetite and contributing to feelings of fullness. Although the U.S. Food and Drug Administration approved Ozempic to treat Type 2 diabetes, doctors now commonly prescribe it off-label for weight management. About 1 in 8 adults in the U.S. has used a GLP-1 drug, and of those, around 2 in 5 did so solely to lose weight, according to health policy non-profit KFF in 2024. Today, more than 20% of Frank's patients are using GLP-1s as part of what he called their 'longevity regimen.' The treatments sought after their weight loss include injectable dermal fillers to help restore facial volume, facelifts and fat transfers. 'You can only refill a deflated balloon so much, and often surgical intervention is necessary,' he said. But for many patients, he added, 'just upping the dosage of their volume replacement is more than enough. 'Someone who may have used one syringe of filler in the past is now using two or three.' 'It looked like I had melted' The American Society of Plastic Surgeons (ASPS), which publishes an annual report on surgery trends, recently found that 2 in 5 of its members' GLP-1 patients were considering undergoing cosmetic surgery — and 1 in 5 already had. Among the patients opting for a facelift was Kimberly Bongiorno, a local government land use administrator from Mount Arlington, New Jersey. Having lost weight after gastric sleeve surgery in 2019, she regained 40 pounds during the COVID-19 pandemic and was prescribed Wegovy last year. Despite describing the drug's impact as 'almost a miracle' — taking her weight from 170 to 125 pounds — the 55-year-old faced new concerns over her appearance. 'Everything just kind of hung and was very loose,' she said over Zoom, recalling seeing her face in a photo shared by a friend. 'I no longer felt like I had cheeks, and I had a lot of loose skin under my neck. 'It looked like I had melted. It was horrifying,' she added. 'It was so disheartening to see how my face looked and how it had changed, I thought I looked a lot older than I am.' After consulting plastic surgeon Dr. Anthony Berlet at his New Jersey office, Bongiorno underwent a deep plane facelift that lifted her skin and repositioned some of the deeper muscles and connective tissues. She also opted for a neck lift that refined and smoothed her neck contours while addressing excess skin left by her weight loss. 'Before I did this, I probably looked closer to 60, or maybe even older. And now I have people who I've recently met think I am in my 40s,' Bongiorno said, adding: 'People I haven't seen in a while say, 'You look so healthy and happy.' And that's nice to hear, because for a while, I didn't look healthy and certainly wasn't happy.' The number of facelifts performed in the U.S. jumped 8% between 2022 and 2023, according to ASPS data. The use of hyaluronic acid fillers has meanwhile doubled from 2.6 million Americans in 2017 — the year Ozempic was first cleared for diabetes — to over 5.2 million in 2023. The organization could not attribute these upticks exclusively to GLP-1 use, but its former president, Dr. Steven Williams, said the medications have had 'a global effect on aesthetic surgery.' 'Now we have a brand-new tool that actually has efficacy for so many patients,' said Williams, a board-certified plastic surgeon and founder of California's Tri Valley Plastic Surgery, over Zoom. He noted that GLP-1s come 'without substantial drawbacks' when compared with invasive procedures like gastric bypass surgery. 'We can now have an honest conversation with patients about a nonsurgical tool that's effective in weight loss,' he added. 'And as part of that conversation, there's an obligation to say, 'Look, this is really going to work, so you have to be prepared for what looking 20 or 50 pounds slimmer is going to be.'' The term 'Ozempic face' may speak to our times, but its symptoms — caused by a decrease in the subcutaneous fat that makes our faces plump — are nothing new. Cosmetic surgeons have long been treating the side effects of significant weight loss. In fact, one popular brand of dermal filler, Sculptra, was originally developed in the 1990s for HIV patients. As an adult, 'your body actually doesn't make more fat cells,' Williams said. 'As we lose or gain weight, those fat cells aren't multiplying or decreasing; they're getting bigger or smaller. And so as we lose weight, those fat cells now have decreased volume, and there's just less fullness.' Preventive measures Age can determine how patients' faces react to weight loss. People in their 20s and 30s, for instance, are far less likely to experience the appearance of aging due to GLP-1 use, Frank said. 'Because they have good skin elasticity, the skin rebounds much better,' he said. Patients aged 20 to 39 accounted for 14% of hyaluronic acid filler use in the U.S. and just 2% of facelift procedures last year, according to the ASPS. But both figures are on the rise. Gabriela Vasquez, 29, is among the younger patients using GLP-1 to undergo cosmetic procedures after rapid weight loss. An employee of one of Williams' Tri Valley Plastic Surgery clinics, she has dropped around 50 pounds since starting Ozempic in November. Although Vasquez is still working toward her target weight, she sought preventative Botox injections (more visible lines and wrinkles are, along with thinning lips, among the other side effects of GLP-1 use). She has also recently undergone microneedling, a procedure used to stimulate collagen production. 'One of my concerns was my jowls, because I felt I saw them when I was a little heavier,' she said over Zoom from the Bay Area. 'I think the microneedling definitely helped. 'I never had a jaw line,' she added. 'And a couple weeks ago, someone took a picture of me, and I had one, and I was like, 'Well, that's new.'' Vasquez did not rule out further cosmetic procedures as she continues losing weight — and not only to her face and neck. 'I'm seeing little things in my body that I'm like, 'Whoa, that would be nice to take care of,'' she said, referencing the appearance of excess skin under her arms. 'I could see myself — later down the line, once I get to my goal weight — doing something to kind of tighten everything up.' Frank, the cosmetic dermatologist, noted that 'Ozempic face' may be accompanied by a phenomenon he dubbed 'Ozempic body,' adding: 'One of the other major side effects of weight loss, particularly when it's done at a rate of more than one to two pounds a week, is muscle loss. And we see this all over the body.' The ASPS similarly notes the emerging term 'Ozempic makeover,' a suite of procedures that might also include tummy tucks, breast lifts and arm, thigh and buttock lifts. For instance, Bongiorno, the New Jersey facelift patient, has also undergone several other procedures with Dr. Berlet, including arm and thigh lifts, to address her excess skin. She estimates that after her upcoming breast lift, fat grafting and lower eyelid surgery, she will have spent about $80,000 on cosmetic procedures. 'Skin is heavy and uncomfortable,' she said. 'This wasn't something I did to go out there and be a supermodel. It was just to be comfortable, so I could get clothes on and not feel like I was dragging around all this extra weight.' Ongoing questions The long-term effect of GLP-1 medications on cosmetic medicine is yet to be fully understood. The assumption they might reduce demand for liposuction, for instance, has not come to bear: It remains the most common cosmetic surgical procedure in the US, growing in popularity by 1% last year, per ASPS data. What also remains to be seen is the effect that 'Ozempic rebound' — when patients regain weight after stopping the drugs — has on people who sought cosmetic procedures. A recent peer-reviewed study found that most people using the drugs for weight loss quit within a year. Data presented at this year's European Congress on Obesity meanwhile suggested that patients typically returned to their original weight within 10 months of stopping use, with University of Oxford researchers calling the findings a 'cautionary note' about using medication 'without a more comprehensive approach' to weight loss. For Williams, this further demonstrates why he and his plastic surgeon colleagues must take responsibility for their patients' 'entire journey,' not just their cosmetic procedures. 'We don't want these patients to be on these medications for a lifetime. We want it to be a temporary bridge to a healthier lifestyle,' he said, adding: 'It's our obligation to work harder with those patients, to talk about lifestyle changes, to get them plugged in to dietitians and to make sure that they're building muscle and exercising.' By Oscar Holland, CNN

McGill University team develops AI that can detect infection before symptoms appear
McGill University team develops AI that can detect infection before symptoms appear

CTV News

time22 minutes ago

  • CTV News

McGill University team develops AI that can detect infection before symptoms appear

Participants wore a smart ring, a smart watch, and a smart T-shirt that monitored multiple physiological parameters and activities. In the photo, an Apple Watch in 2015 in Tokyo. (Koji Sasahara, File/AP Photo) MONTRÉAL — Researchers at McGill University say they developed an artificial intelligence platform that can predict when someone is about to come down with a respiratory tract infection before they start to feel sick. In what researchers are calling a 'world first,' the study involved participants who wore a ring, a watch and a T-shirt, all of which were equipped with censors that recorded their biometric data. By analyzing the data, researchers were able to accurately predict acute systemic inflammation — an early sign of a respiratory infection such as COVID-19. Published in The Lancet Digital Health, the study says the AI platform can one day help doctors address health problems much earlier than they normally would, particularly in patients who are fragile and for whom a new infection could have serious consequences. It could also potentially reduce costs for the health-care system by preventing complications and hospitalizations. 'We were very interested to see if physiological data measured using wearable sensors … could be used to train an artificial intelligence system capable of detecting an infection or disease resulting from inflammation,' explained the study's lead author, Prof. Dennis Jensen of McGill University's department of kinesiology and physical education. 'We wondered if we could detect early changes in physiology and, from there, predict that someone is about to get sick.' Jense says the AI model his team created is the first in the world to use physiological measures — including heart rate, heart rate variability, body temperature, respiratory rate, blood pressure — rather than symptoms, to detect a problem. Acute systemic inflammation is a natural defence mechanism of the body that usually resolves on its own, but it can cause serious health problems, especially in populations with pre-existing conditions. 'The whole idea is kind of like an iceberg,' Jensen said. 'Kind of when the ice cracks the surface, that's like when you're symptomatic, and then it's too late to really do much to treat it.' During the study, McGill researchers administered a weakened flu vaccine to 55 healthy adults to simulate infection in their bodies. The subjects were monitored seven days before inoculation and five days after. Participants wore a smart ring, smart watch, and a smart T-shirt simultaneously throughout the study. As well, researchers collected biomarkers of systemic inflammation using blood samples, PCR tests to detect the presence of respiratory pathogens, and a mobile app to collect symptoms reported by participants. In total, more than two billion data points were collected to train machine learning algorithms. Ten different AI models were developed, but the researchers chose the model that used the least amount of data for the remainder of the project. The chosen model correctly detected nearly 90 per cent of actual positive cases and was deemed more practical for daily monitoring. On their own, Jensen said, none of the data collected from the ring, watch, or T-shirt alone is sensitive enough to detect how the body is responding. 'An increase in heart rate alone may only correspond to two beats per minute, which is not really clinically relevant,' he explained. 'The decrease in heart rate variability can be very modest. The increase in temperature can be very modest. So the idea was that by looking at … several different measurements, we would be able to identify subtle changes in physiology.' The algorithms also successfully detected systemic inflammation in four participants infected with COVID-19 during the study. In each case, the algorithms flagged the immune response up to 72 hours before symptoms appeared or infection was confirmed by PCR testing. Ultimately, the researchers hope to develop a system that will inform patients of possible inflammation so they can contact their health-care provider. 'In medicine, we say that you have to give the right treatment to the right person at the right time,' Jensen said. By expanding the therapeutic window in which doctors can intervene, he added, they could save lives and achieve significant savings by avoiding hospitalizations and enabling home management of chronic conditions or even aging. 'In a way, we hope to revolutionize personalized medicine.' This report by The Canadian Press was first published July 30, 2025. By Jean-Benoit Legault, The Canadian Press

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store